Economic impact of integrated care models for patients with chronic diseases: A systematic review

Melissa Desmedt, Sonja Vertriest, Johan Hellings, Jochen Bergs, Ezra Dessers, Patrik Vankrunkelsven, H.J.M. Vrijhoef, Lieven Annemans, Nick Verhaeghe, Mirko Petrovic, Dominique Vandijck

Research output: Contribution to journalArticleScientificpeer-review

Abstract

Objectives
To assess the costs and potential financial benefits of integrated care models for patients with chronic diseases, that is, type 2 diabetes mellitus, schizophrenia, and multiple sclerosis, respectively.
Methods
A systematic search of the literature was performed using EMBASE, MEDLINE, and Web of Science. Studies that conducted a cost analysis, considered at least two components of the chronic care model, and compared integrated care with standard care were included.
Results
Out of 575 articles, 26 were included. Most studies examined integrated care models for type 2 diabetes mellitus (n = 18) and to a lesser extent for schizophrenia (n = 6) and multiple sclerosis (n = 2). Across the three disease groups, the incremental cost per patient per year ranged from − €3860 to + €613.91 (
= − €533.61 ± €902.96). The incremental cost for type 2 diabetes mellitus ranged from − €1507.49 to + €299.20 ( = − €518.22 ± + €604.75), for schizophrenia from − €3860 to + €613.91 ( = − €677.21 ± + €1624.35), and for multiple sclerosis from − €822 to + €339.43 (= − €241.29 ± + €821.26). Most of the studies (22 of 26 [84.6%]) reported a positive economic impact of integrated care models: for type 2 diabetes mellitus (16 of 18 [88.9%]), schizophrenia (4 of 6 [66.7%]), and multiple sclerosis (1 of 2 [50%]).
Conclusions
In this systematic literature review, predominantly positive economic impacts of integrated care models for patients with chronic diseases were found.
Keywords: chronic disease, cost analysis, integrated care, multiple sclerosis,
schizophrenia, type 2 diabetes mellitus
Original languageEnglish
Pages (from-to)892-902
JournalValue in Health
Volume19
Issue number6
DOIs
Publication statusPublished - 1 Sep 2016

Fingerprint

Type 2 Diabetes Mellitus
Cost of Illness
MEDLINE

Cite this

Desmedt, M., Vertriest, S., Hellings, J., Bergs, J., Dessers, E., Vankrunkelsven, P., ... Vandijck, D. (2016). Economic impact of integrated care models for patients with chronic diseases: A systematic review. Value in Health, 19(6), 892-902. https://doi.org/10.1016/j.jval.2016.05.001
Desmedt, Melissa ; Vertriest, Sonja ; Hellings, Johan ; Bergs, Jochen ; Dessers, Ezra ; Vankrunkelsven, Patrik ; Vrijhoef, H.J.M. ; Annemans, Lieven ; Verhaeghe, Nick ; Petrovic, Mirko ; Vandijck, Dominique. / Economic impact of integrated care models for patients with chronic diseases : A systematic review. In: Value in Health. 2016 ; Vol. 19, No. 6. pp. 892-902.
@article{2e2cf068e7344569970c529b4071fb1a,
title = "Economic impact of integrated care models for patients with chronic diseases: A systematic review",
abstract = "ObjectivesTo assess the costs and potential financial benefits of integrated care models for patients with chronic diseases, that is, type 2 diabetes mellitus, schizophrenia, and multiple sclerosis, respectively.MethodsA systematic search of the literature was performed using EMBASE, MEDLINE, and Web of Science. Studies that conducted a cost analysis, considered at least two components of the chronic care model, and compared integrated care with standard care were included.ResultsOut of 575 articles, 26 were included. Most studies examined integrated care models for type 2 diabetes mellitus (n = 18) and to a lesser extent for schizophrenia (n = 6) and multiple sclerosis (n = 2). Across the three disease groups, the incremental cost per patient per year ranged from − €3860 to + €613.91 (= − €533.61 ± €902.96). The incremental cost for type 2 diabetes mellitus ranged from − €1507.49 to + €299.20 ( = − €518.22 ± + €604.75), for schizophrenia from − €3860 to + €613.91 ( = − €677.21 ± + €1624.35), and for multiple sclerosis from − €822 to + €339.43 (= − €241.29 ± + €821.26). Most of the studies (22 of 26 [84.6{\%}]) reported a positive economic impact of integrated care models: for type 2 diabetes mellitus (16 of 18 [88.9{\%}]), schizophrenia (4 of 6 [66.7{\%}]), and multiple sclerosis (1 of 2 [50{\%}]).ConclusionsIn this systematic literature review, predominantly positive economic impacts of integrated care models for patients with chronic diseases were found.Keywords: chronic disease, cost analysis, integrated care, multiple sclerosis,schizophrenia, type 2 diabetes mellitus",
author = "Melissa Desmedt and Sonja Vertriest and Johan Hellings and Jochen Bergs and Ezra Dessers and Patrik Vankrunkelsven and H.J.M. Vrijhoef and Lieven Annemans and Nick Verhaeghe and Mirko Petrovic and Dominique Vandijck",
year = "2016",
month = "9",
day = "1",
doi = "10.1016/j.jval.2016.05.001",
language = "English",
volume = "19",
pages = "892--902",
journal = "Value in Health",
issn = "1098-3015",
publisher = "Elsevier Limited",
number = "6",

}

Desmedt, M, Vertriest, S, Hellings, J, Bergs, J, Dessers, E, Vankrunkelsven, P, Vrijhoef, HJM, Annemans, L, Verhaeghe, N, Petrovic, M & Vandijck, D 2016, 'Economic impact of integrated care models for patients with chronic diseases: A systematic review', Value in Health, vol. 19, no. 6, pp. 892-902. https://doi.org/10.1016/j.jval.2016.05.001

Economic impact of integrated care models for patients with chronic diseases : A systematic review. / Desmedt, Melissa; Vertriest, Sonja; Hellings, Johan; Bergs, Jochen; Dessers, Ezra; Vankrunkelsven, Patrik; Vrijhoef, H.J.M.; Annemans, Lieven; Verhaeghe, Nick; Petrovic, Mirko; Vandijck, Dominique.

In: Value in Health, Vol. 19, No. 6, 01.09.2016, p. 892-902.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Economic impact of integrated care models for patients with chronic diseases

T2 - A systematic review

AU - Desmedt, Melissa

AU - Vertriest, Sonja

AU - Hellings, Johan

AU - Bergs, Jochen

AU - Dessers, Ezra

AU - Vankrunkelsven, Patrik

AU - Vrijhoef, H.J.M.

AU - Annemans, Lieven

AU - Verhaeghe, Nick

AU - Petrovic, Mirko

AU - Vandijck, Dominique

PY - 2016/9/1

Y1 - 2016/9/1

N2 - ObjectivesTo assess the costs and potential financial benefits of integrated care models for patients with chronic diseases, that is, type 2 diabetes mellitus, schizophrenia, and multiple sclerosis, respectively.MethodsA systematic search of the literature was performed using EMBASE, MEDLINE, and Web of Science. Studies that conducted a cost analysis, considered at least two components of the chronic care model, and compared integrated care with standard care were included.ResultsOut of 575 articles, 26 were included. Most studies examined integrated care models for type 2 diabetes mellitus (n = 18) and to a lesser extent for schizophrenia (n = 6) and multiple sclerosis (n = 2). Across the three disease groups, the incremental cost per patient per year ranged from − €3860 to + €613.91 (= − €533.61 ± €902.96). The incremental cost for type 2 diabetes mellitus ranged from − €1507.49 to + €299.20 ( = − €518.22 ± + €604.75), for schizophrenia from − €3860 to + €613.91 ( = − €677.21 ± + €1624.35), and for multiple sclerosis from − €822 to + €339.43 (= − €241.29 ± + €821.26). Most of the studies (22 of 26 [84.6%]) reported a positive economic impact of integrated care models: for type 2 diabetes mellitus (16 of 18 [88.9%]), schizophrenia (4 of 6 [66.7%]), and multiple sclerosis (1 of 2 [50%]).ConclusionsIn this systematic literature review, predominantly positive economic impacts of integrated care models for patients with chronic diseases were found.Keywords: chronic disease, cost analysis, integrated care, multiple sclerosis,schizophrenia, type 2 diabetes mellitus

AB - ObjectivesTo assess the costs and potential financial benefits of integrated care models for patients with chronic diseases, that is, type 2 diabetes mellitus, schizophrenia, and multiple sclerosis, respectively.MethodsA systematic search of the literature was performed using EMBASE, MEDLINE, and Web of Science. Studies that conducted a cost analysis, considered at least two components of the chronic care model, and compared integrated care with standard care were included.ResultsOut of 575 articles, 26 were included. Most studies examined integrated care models for type 2 diabetes mellitus (n = 18) and to a lesser extent for schizophrenia (n = 6) and multiple sclerosis (n = 2). Across the three disease groups, the incremental cost per patient per year ranged from − €3860 to + €613.91 (= − €533.61 ± €902.96). The incremental cost for type 2 diabetes mellitus ranged from − €1507.49 to + €299.20 ( = − €518.22 ± + €604.75), for schizophrenia from − €3860 to + €613.91 ( = − €677.21 ± + €1624.35), and for multiple sclerosis from − €822 to + €339.43 (= − €241.29 ± + €821.26). Most of the studies (22 of 26 [84.6%]) reported a positive economic impact of integrated care models: for type 2 diabetes mellitus (16 of 18 [88.9%]), schizophrenia (4 of 6 [66.7%]), and multiple sclerosis (1 of 2 [50%]).ConclusionsIn this systematic literature review, predominantly positive economic impacts of integrated care models for patients with chronic diseases were found.Keywords: chronic disease, cost analysis, integrated care, multiple sclerosis,schizophrenia, type 2 diabetes mellitus

U2 - 10.1016/j.jval.2016.05.001

DO - 10.1016/j.jval.2016.05.001

M3 - Article

VL - 19

SP - 892

EP - 902

JO - Value in Health

JF - Value in Health

SN - 1098-3015

IS - 6

ER -

Desmedt M, Vertriest S, Hellings J, Bergs J, Dessers E, Vankrunkelsven P et al. Economic impact of integrated care models for patients with chronic diseases: A systematic review. Value in Health. 2016 Sep 1;19(6):892-902. https://doi.org/10.1016/j.jval.2016.05.001